Literature DB >> 30030816

Model Structuring for Economic Evaluations of New Health Technologies.

Hossein Haji Ali Afzali1, Laura Bojke2, Jonathan Karnon3.   

Abstract

In countries such as Australia, the UK and Canada, decisions on whether to fund new health technologies are commonly informed by decision analytic models. While the impact of making inappropriate structural choices/assumptions on model predictions is well noted, there is a lack of clarity about the definition of key structural aspects, the process of developing model structure (including the development of conceptual models) and uncertainty associated with the structuring process (structural uncertainty) in guidelines developed by national funding bodies. This forms the focus of this article. Building on the reports of good modelling practice, and recognising the fundamental role of model structuring within the model development process, we specified key structural choices and provided ideas about model structuring for the future direction. This will help to further standardise guidelines developed by national funding bodies, with potential impact on transparency, comprehensiveness and consistency of model structuring. We argue that the process of model structuring and structural sensitivity analysis should be documented in a more systematic and transparent way in submissions to national funding bodies. Within the decision-making process, the development of conceptual models and presentation of all key structural choices would mean that national funding bodies could be more confident of maximising value for money when making public funding decisions.

Mesh:

Year:  2018        PMID: 30030816     DOI: 10.1007/s40273-018-0693-7

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  40 in total

1.  Modelling in the economic evaluation of health care: selecting the appropriate approach.

Authors:  Pelham Barton; Stirling Bryan; Suzanne Robinson
Journal:  J Health Serv Res Policy       Date:  2004-04

Review 2.  Cost-effectiveness as an outcome in randomized clinical trials.

Authors:  Mark A Hlatky; Douglas K Owens; Gillian D Sanders
Journal:  Clin Trials       Date:  2006       Impact factor: 2.486

3.  Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs.

Authors:  M Brisson; W J Edmunds
Journal:  Med Decis Making       Date:  2006 Sep-Oct       Impact factor: 2.583

4.  Use of evidence in economic decision models: practical issues and methodological challenges.

Authors:  N J Cooper; A J Sutton; A E Ades; S Paisley; D R Jones
Journal:  Health Econ       Date:  2007-12       Impact factor: 3.046

5.  Modelling in economic evaluation: an unavoidable fact of life.

Authors:  M J Buxton; M F Drummond; B A Van Hout; R L Prince; T A Sheldon; T Szucs; M Vray
Journal:  Health Econ       Date:  1997 May-Jun       Impact factor: 3.046

6.  Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6.

Authors:  Andrew H Briggs; Milton C Weinstein; Elisabeth A L Fenwick; Jonathan Karnon; Mark J Sculpher; A David Paltiel
Journal:  Value Health       Date:  2012 Sep-Oct       Impact factor: 5.725

7.  Smoking Cessation: A Comparison of Two Model Structures.

Authors:  Becky Pennington; Alex Filby; Lesley Owen; Matthew Taylor
Journal:  Pharmacoeconomics       Date:  2018-09       Impact factor: 4.981

Review 8.  A critical review of model-based economic studies of depression: modelling techniques, model structure and data sources.

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon; Jodi Gray
Journal:  Pharmacoeconomics       Date:  2012-06-01       Impact factor: 4.981

9.  A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.

Authors:  Patrick W Sullivan; Robert Valuck; Joseph Saseen; Holly M MacFall
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

10.  Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.

Authors:  K Claxton; S Palmer; L Longworth; L Bojke; S Griffin; C McKenna; M Soares; E Spackman; J Youn
Journal:  Health Technol Assess       Date:  2012       Impact factor: 4.014

View more
  4 in total

1.  Model parameters influencing the cost-effectiveness of sacubitril/valsartan in heart failure: evidence from a systematic literature review.

Authors:  Clare Proudfoot; Raju Gautam; Joaquim Cristino; Rumjhum Agrawal; Lalit Thakur; Keith Tolley
Journal:  Eur J Health Econ       Date:  2022-07-05

2.  Hierarchical Structure Model of Safety Risk Factors in New Coastal Towns: A Systematic Analysis Using the DEMATEL-ISM-SNA Method.

Authors:  Chenlei Guan; Damin Dong; Feng Shen; Xin Gao; Linyan Chen
Journal:  Int J Environ Res Public Health       Date:  2022-08-23       Impact factor: 4.614

3.  Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer.

Authors:  Zhiwei Zheng; Huide Zhu; Ling Fang; Hongfu Cai
Journal:  Front Pharmacol       Date:  2022-09-12       Impact factor: 5.988

4.  Structuring a conceptual model for cost-effectiveness analysis of frailty interventions.

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon; Olga Theou; Justin Beilby; Matteo Cesari; Renuka Visvanathan
Journal:  PLoS One       Date:  2019-09-11       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.